Htn medications
Searched over 200M research papers for "htn medications"
Summary
10 papers analyzed
These studies suggest that antihypertensive medications can reduce cardiovascular risks, improve clinical outcomes in certain cancers, and are crucial for effective blood pressure control, though adherence is often suboptimal.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Hypertension Medications: Efficacy, Adherence, and Outcomes
Efficacy of Antihypertensive Medications in Heart Failure with Preserved Ejection Fraction (HFpEF)
Hypertension (HTN) is a common comorbidity in patients with heart failure with preserved ejection fraction (HFpEF). A meta-analysis of 15 studies involving 17,507 HFpEF patients evaluated the impact of antihypertensive medications (AHM) on cardiovascular (CV) outcomes. The findings indicated that while AHM did not significantly reduce all-cause or CV mortality, they were associated with a lower risk of major adverse cardiovascular events (MACE) and CV hospitalization. This suggests that AHM may benefit HFpEF patients by reducing adverse CV outcomes, although further research is needed to clarify these associations and the effects of specific medication classes.
Hypertension as a Biomarker in Cancer Treatment
Hypertension has been identified as a potential biomarker for the efficacy of certain cancer treatments. In patients with gastrointestinal stromal tumors (GIST) treated with sunitinib, the development of HTN was significantly associated with improved clinical outcomes, including overall survival (OS) and progression-free survival (PFS). Similarly, in patients with advanced non-adipocytic soft tissue sarcoma treated with pazopanib, HTN was evaluated as a biomarker, but no significant correlation with treatment outcomes was found. These findings highlight the complex role of HTN in cancer therapy and the need for further investigation.
Management of Hypertension in Hypertrophic Cardiomyopathy (HCM)
Managing HTN in patients with hypertrophic cardiomyopathy (HCM) presents unique challenges. A scoping review of the literature revealed that over 50% of adults with HCM have co-occurring HTN, and the use of certain antihypertensive medications can worsen obstructive HCM (OHCM). The review highlighted the need for careful selection of medications, with beta-1 selective blockers and verapamil showing some promise in improving functional outcomes and blood pressure control. However, the heterogeneity in study designs and outcomes underscores the necessity for more targeted research in this area.
Adherence to Antihypertensive Medications
Adherence to antihypertensive medications is crucial for effective blood pressure control and improved health outcomes. Despite the availability of effective antihypertensive drugs, non-adherence remains a significant barrier to optimal HTN management. Strategies to improve adherence, such as patient education and mobile health interventions, are essential to achieving better control of HTN and reducing associated morbidity and mortality.
Hypertension and Renal Transplant Outcomes
In pediatric renal transplant recipients, the use of antihypertensive medications was associated with higher rates of subsequent graft failure. This association was particularly pronounced in patients with cadaveric donor grafts and those who experienced acute rejection episodes. These findings suggest that post-transplant HTN, as evidenced by the need for antihypertensive medications, is a marker of increased risk for graft failure.
Hypertension Control in Systemic Lupus Erythematosus (SLE)
Hypertension is a common comorbidity in patients with systemic lupus erythematosus (SLE) and is a key risk factor for cardiovascular and renal disease. A cross-sectional study found that a significant proportion of SLE patients had uncontrolled HTN despite being on antihypertensive medications. Factors associated with uncontrolled HTN included higher body mass index (BMI) and Caucasian ethnicity, while patients with renal damage had better HTN control, likely due to more aggressive management.
Antihypertensive Medications and New-Onset Diabetes
The use of certain antihypertensive medications has been linked to the development of new-onset diabetes (NOD). A study in South Indian patients found that combination therapy and specific drug classes, such as angiotensin II receptor blockers and diuretics, were associated with a higher risk of NOD. This highlights the importance of monitoring glucose levels in patients on these medications and considering the risk of diabetes when selecting antihypertensive therapy.
Endovascular Ultrasound Renal Denervation for Hypertension Control
The RADIANCE-HTN SOLO trial demonstrated that endovascular ultrasound renal denervation (RDN) significantly reduced daytime ambulatory systolic blood pressure compared to a sham procedure. At six months, patients who underwent RDN required fewer antihypertensive medications to achieve similar blood pressure control, indicating the potential of RDN as an effective treatment for HTN.
Mobile Health Interventions to Improve Medication Adherence
Mobile health (mHealth) strategies, such as text messaging, have shown promise in improving medication adherence among African Americans with uncontrolled HTN. Feasibility studies indicated that text message reminders were well-received and led to improvements in medication adherence and blood pressure control, suggesting that mHealth interventions could be a valuable tool in HTN management.
Conclusion
The management of hypertension involves a multifaceted approach, including the selection of appropriate medications, ensuring patient adherence, and considering comorbid conditions. While antihypertensive medications are effective in controlling blood pressure and reducing adverse outcomes, challenges such as non-adherence and the risk of new-onset diabetes must be addressed. Innovative treatments like renal denervation and mHealth interventions offer promising avenues for improving HTN management and patient outcomes. Further research is needed to optimize treatment strategies and address the complexities of HTN in various patient populations.
Sources and full results
Most relevant research papers on this topic
